Buprenorphine hydrochloride

Base Information

• Chemical Name: Buprenorphine hydrochloride
• CAS No.: 53152-21-9
• Deprecated CAS: 53187-13-6,55327-62-3,64425-21-4
• Molecular Formula: C29H41 N O4 . Cl H
• Molecular Weight: 504.17
• Hs Code.: 2939110000
• European Community (EC) Number: 258-396-8
• UNII: 56W8MW3EN1
• DSSTox Substance ID: DTXSID2048905
• Wikidata: Q27105186
• NCI Thesaurus Code: C47424
• RXCUI: 203841
• Mol file: 53152-21-9.mol

Synonyms:6029 M;6029-M;6029M;Buprenex;Buprenorphine;Buprenorphine Hydrochloride;Buprex;Hydrochloride, Buprenorphine;Prefin;RX 6029 M;RX-6029-M;RX6029M;Subutex;Temgésic;Temgesic

 This product is a nationally controlled contraband, and the Lookchem platform doesn't provide relevant sales information.

Chemical Property of Buprenorphine hydrochloride

Chemical Property:

• Melting Point: 260-262?C (dec.)
• Boiling Point: °Cat760mmHg
• Flash Point: °C
• PSA: 62.16000
• Density: 1.26g/cm³
• LogP: 5.15370
• Storage Temp.: -0°C
• Solubility.: Sparingly soluble in water, freely soluble in methanol, soluble in ethanol (96 per cent), practically insoluble in cyclohexane.
• Hydrogen Bond Donor Count: 3
• Hydrogen Bond Acceptor Count: 5
• Rotatable Bond Count: 5
• Exact Mass: 503.2802365
• Heavy Atom Count: 35
• Complexity: 869

Purity/Quality:

Safty Information:

• Pictogram(s): Xn,T,F
• Hazard Codes: Xn,T,F
• Statements: 22-62-63-39/23/24/25-23/24/25-11
• Safety Statements: 26-36-45-36/37-16-7

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: CC(C)(C)C(C)(C1CC23CCC1(C4C25CCN(C3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)O.Cl
• Isomeric SMILES: C[C@]([C@H]1C[C@@]23CC[C@@]1([C@H]4[C@@]25CCN([C@@H]3CC6=C5C(=C(C=C6)O)O4)CC7CC7)OC)(C(C)(C)C)O.Cl
• Recent ClinicalTrials: Multiple Dose Pharmacokinetics Depot Buprenorphine in Opioid-Dependent Subjects
• Recent EU Clinical Trials: Extended-release Pharmacotherapy for Opioid Use Disorder (EXPO): An Open Label Randomised Controlled Trial of Injectable Depot Maintenance Buprenorphine versus Standard-Of-Care Oral Maintenance Opioid Agonist/Partial Opioid Agonist Medication, with Personalised Psychosocial Intervention
• Description: Buprenorphine (hydrochloride) (CRM) (Item No. ISO60178) is a certified reference material that is structurally categorized as an opioid. It is a partial agonist of the μ-opioid receptor (Ki = 4.18 nM) that less potently acts at δ- and κ-opioid receptors (Kis = 25.8 and 12.9 nM, respectively). Buprenorphine is used, alone or with naloxone (Item Nos. ISO60194 | 15594), to counter opiate addiction. This product is intended for research and forensic applications.
• Clinical Use: Buprenorphine undergoes extensive first-pass 3-O-glucuronidation, which negates its usefulness after oral dose. It is available in parenteral and sublingual dosage forms. The typical dose is 0.3 to 0.6 mg three times per day by intramuscular injection for analgesia or 8 mg/day as a sublingual tablet for opioid-dependence maintenance. The duration of analgesic effect is 4 to 6 hours. After parenteral dose, approximately 70% of the drug is excreted in the feces, and the remainder appears as N-dealkylated and conjugated metabolites in the urine. Naloxone is not an effective antagonist to buprenorphine because of the latter's high binding affinity to opioid receptors.